Lifecore Biomedical (LFCR) Stock Price

Lifecore Biomedical Price

NASDAQ·CLOSED
4.84USD+0.46 (+9.98 %)
Market closed

Revenue at Lifecore Biomedical has contracted by 2.5% per year over the past 19 years to 129.46 M USD. Earnings per share have declined at 6.4% per year over the last 17 years. Lifecore Biomedical's net margin stands at -23.8%, up from -52.4% several years earlier. Analysts set a median price target of 8.93 USD, implying 84.4% above the current price. Of 11 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 32% above its 52-week low.

Lifecore Biomedical stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Lifecore Biomedical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Lifecore Biomedical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Lifecore Biomedical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Lifecore Biomedical Stock Price History
DateLifecore Biomedical Price
8/6/20264.84 USD
8/5/20264.38 USD
8/4/20264.41 USD
8/3/20264.39 USD
7/31/20264.42 USD
7/30/20264.36 USD
7/29/20264.26 USD
7/27/20264.34 USD
7/23/20264.43 USD
7/22/20264.58 USD
7/21/20264.64 USD
7/20/20264.69 USD
7/17/20264.68 USD
7/16/20264.95 USD
7/15/20264.86 USD
7/14/20264.61 USD
7/13/20264.78 USD
7/10/20264.75 USD
7/9/20264.75 USD
7/8/20264.64 USD
7/7/20264.86 USD
7/6/20265.07 USD
7/2/20265.09 USD
7/1/20265.27 USD
6/30/20265.25 USD
6/29/20264.96 USD
6/26/20265.17 USD
6/25/20265.39 USD
6/24/20265.80 USD
6/23/20265.66 USD
6/22/20265.52 USD
6/18/20265.54 USD
6/17/20265.52 USD
6/16/20265.35 USD
6/15/20265.49 USD
6/12/20265.64 USD
6/11/20265.65 USD
6/10/20265.65 USD
6/9/20265.66 USD
6/8/20265.57 USD
6/5/20265.63 USD
6/4/20265.79 USD
6/3/20265.67 USD
6/2/20265.45 USD
6/1/20264.85 USD
5/29/20265.02 USD
5/28/20264.97 USD
5/27/20264.82 USD
5/26/20264.80 USD
5/22/20264.93 USD
5/21/20264.98 USD
5/20/20264.57 USD
5/19/20264.38 USD
5/18/20264.38 USD
5/15/20264.40 USD
5/14/20264.55 USD
5/13/20264.50 USD
5/12/20264.56 USD
5/11/20264.50 USD
5/8/20264.79 USD
5/7/20264.77 USD
5/6/20264.96 USD
5/5/20265.16 USD
5/4/20265.13 USD
5/1/20265.26 USD
4/30/20265.07 USD
4/29/20264.94 USD
4/28/20265.12 USD
4/27/20265.08 USD
4/24/20265.02 USD
4/23/20265.03 USD
4/22/20265.23 USD
4/21/20265.23 USD
4/20/20265.35 USD
4/17/20265.38 USD
4/16/20265.20 USD
4/15/20265.38 USD
4/14/20265.20 USD
4/13/20264.94 USD
4/10/20264.75 USD
4/9/20264.72 USD
4/8/20264.24 USD
4/7/20264.11 USD
4/6/20264.07 USD
4/2/20263.84 USD
4/1/20263.84 USD
3/31/20263.72 USD
3/30/20263.79 USD
3/27/20263.66 USD
3/26/20263.87 USD
3/25/20264.19 USD
3/24/20264.00 USD
3/23/20264.05 USD
3/20/20264.02 USD
3/19/20264.06 USD
3/18/20264.15 USD
3/17/20264.36 USD
3/16/20264.37 USD
3/13/20266.54 USD
3/12/20266.61 USD
3/11/20266.81 USD
3/10/20266.90 USD
3/9/20266.98 USD
3/6/20266.96 USD
3/5/20267.02 USD
3/4/20267.06 USD
3/3/20266.99 USD
3/2/20267.23 USD
2/27/20267.20 USD
2/26/20267.37 USD
2/25/20267.33 USD
2/24/20267.22 USD
2/23/20267.29 USD
2/20/20267.13 USD
2/19/20267.20 USD
2/18/20267.26 USD
2/17/20267.16 USD
2/13/20267.08 USD
2/12/20267.00 USD
2/11/20267.23 USD
2/10/20267.38 USD
2/9/20267.46 USD
2/6/20267.57 USD
2/5/20267.56 USD
2/4/20267.90 USD
2/3/20267.97 USD
2/2/20268.52 USD
1/30/20268.69 USD
1/29/20268.51 USD
1/28/20268.56 USD
1/27/20268.67 USD
1/26/20268.82 USD
1/23/20268.58 USD
1/22/20268.59 USD
1/21/20268.43 USD
1/20/20268.25 USD
1/16/20268.22 USD
1/15/20268.10 USD
1/14/20267.88 USD
1/13/20267.46 USD
1/12/20267.59 USD
1/9/20267.56 USD
1/8/20267.77 USD
1/7/20267.89 USD
1/6/20267.91 USD
1/5/20267.80 USD
1/2/20267.74 USD
12/31/20258.18 USD
12/30/20258.09 USD
12/29/20258.25 USD
12/26/20258.30 USD
12/24/20258.25 USD
12/23/20258.06 USD
12/22/20258.17 USD
12/19/20258.04 USD
12/18/20258.42 USD
12/17/20258.47 USD
12/16/20257.71 USD
12/15/20257.88 USD
12/12/20257.79 USD
12/11/20257.81 USD
12/10/20257.63 USD
12/9/20257.59 USD
12/8/20257.51 USD
12/5/20257.63 USD
12/4/20257.77 USD
12/3/20257.64 USD
12/2/20257.72 USD
12/1/20257.82 USD
11/28/20257.90 USD
11/26/20257.83 USD
11/25/20257.90 USD
11/24/20257.51 USD
11/21/20257.64 USD
11/20/20257.37 USD
11/19/20257.49 USD
11/18/20257.60 USD
11/17/20257.90 USD
11/14/20257.96 USD
11/13/20257.89 USD
11/12/20258.22 USD
11/11/20257.74 USD
11/10/20257.29 USD
11/7/20256.85 USD
11/6/20256.62 USD
11/5/20256.77 USD
11/4/20256.78 USD
11/3/20257.11 USD
10/31/20257.19 USD
10/30/20257.10 USD
10/29/20257.06 USD
10/28/20256.90 USD
10/27/20256.73 USD
10/24/20256.78 USD
10/23/20256.81 USD
10/22/20256.74 USD
10/21/20256.76 USD
10/20/20256.63 USD
10/17/20256.49 USD
10/16/20256.53 USD
10/15/20256.69 USD
10/14/20256.54 USD
10/13/20256.61 USD
10/10/20256.50 USD
10/9/20256.63 USD
10/8/20256.87 USD
10/7/20256.74 USD
10/6/20256.85 USD
10/3/20256.98 USD
10/2/20257.06 USD
10/1/20257.17 USD
9/30/20257.36 USD
9/29/20257.15 USD
9/26/20257.01 USD
9/25/20256.81 USD
9/24/20257.06 USD
9/23/20257.90 USD
9/22/20257.88 USD
9/19/20257.87 USD
9/18/20257.93 USD
9/17/20257.70 USD
9/16/20257.86 USD
9/15/20257.68 USD
9/12/20257.52 USD
9/11/20257.77 USD
9/10/20257.01 USD
9/9/20257.26 USD
9/8/20257.29 USD
9/5/20257.53 USD
9/4/20257.94 USD
9/3/20257.71 USD
9/2/20257.46 USD
8/29/20257.61 USD
8/28/20257.62 USD
8/27/20257.53 USD
8/26/20257.50 USD
8/25/20257.59 USD
8/22/20257.60 USD
8/21/20257.22 USD
8/20/20257.24 USD
8/19/20257.25 USD
8/18/20257.40 USD
8/15/20257.37 USD
8/14/20257.42 USD
8/13/20257.74 USD
8/12/20257.63 USD
8/11/20257.22 USD
8/8/20257.24 USD
Access this data via the Eulerpool API

Lifecore Biomedical Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
111.27 M USD
-5.22 M USD
-116.72 M USD
Jan 1, 2024
128.26 M USD
27.60 M USD
12.01 M USD
Jan 1, 2025
128.87 M USD
-16.84 M USD
-38.72 M USD
Jan 1, 2026
129.46 M USD
-1.26 M USD
-30.79 M USD
Jan 1, 2027 (e)
122.18 M USD
-10.28 M USD
-36.39 M USD
Jan 1, 2028 (e)
130.24 M USD
-10.96 M USD
-34.30 M USD
Jan 1, 2029 (e)
150.29 M USD
-12.65 M USD
-41.09 M USD
Jan 1, 2030 (e)
182.46 M USD
-15.36 M USD
-22.63 M USD

Lifecore Biomedical Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 8, 2026, 9:28 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2015201620172018201920202021202220232024202520262027e2028e2029e2030e
539.00541.00532.00524.00557.00160.00100.00185.00111.00128.00128.00129.00122.00130.00150.00182.00
13.240.37-1.66-1.506.30-71.27-37.5085.00-40.0015.320.78-5.436.5615.3821.33
12.0612.9415.6014.8914.5424.3838.0027.0335.1432.0331.2531.0131.0131.0131.0131.01
65.0070.0083.0078.0081.0039.0038.0050.0039.0041.0040.0040.0037.8340.3146.5156.43
18.00-19.0015.0011.008.00-25.00-8.00-34.00-5.0027.00-16.00-1.00-10.00-10.00-12.00-15.00
3.34-3.512.822.101.44-15.63-8.00-18.38-4.5021.09-12.50-0.78-8.20-7.69-8.00-8.24
13.00-11.0010.0024.002.00-38.00-32.00-97.00-116.0012.00-38.00-30.00-36.00-34.00-41.00-22.00
-31.58-184.62-190.91140.00-91.67-2,000.00-15.79203.1319.59-110.34-416.67-21.0520.00-5.5620.59-46.34
27.4227.6227.8827.7929.1629.2829.4730.3030.4634.3637.4037.4837.4837.4837.4837.48
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Lifecore Biomedical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Lifecore Biomedical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Lifecore Biomedical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Lifecore Biomedical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Lifecore Biomedical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Lifecore Biomedical stock margins

The Lifecore Biomedical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Lifecore Biomedical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Lifecore Biomedical.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
27.11 %
-18.75 %
-52.44 %
Jan 1, 2023
35.11 %
-4.69 %
-104.89 %
Jan 1, 2024
32.63 %
21.52 %
9.37 %
Jan 1, 2025
31.27 %
-13.07 %
-30.04 %
Jan 1, 2026
31.37 %
-0.97 %
-23.78 %
Jan 1, 2027 (e)
31.37 %
-8.42 %
-29.78 %
Jan 1, 2028 (e)
31.37 %
-8.42 %
-26.33 %
Jan 1, 2029 (e)
31.37 %
-8.42 %
-27.34 %

Lifecore Biomedical Stock Revenue, EBIT, Earnings per Share

The Lifecore Biomedical earnings per share therefore indicates how much revenue Lifecore Biomedical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2022
6.13 USD
-1.15 USD
-3.22 USD
Jan 1, 2023
3.65 USD
-0.17 USD
-3.83 USD
Jan 1, 2024
3.73 USD
0.80 USD
0.35 USD
Jan 1, 2025
3.45 USD
-0.45 USD
-1.04 USD
Jan 1, 2026
3.45 USD
-0.03 USD
-0.82 USD
Jan 1, 2027 (e)
3.51 USD
-0.27 USD
-1.05 USD
Jan 1, 2028 (e)
3.74 USD
-0.29 USD
-0.99 USD
Jan 1, 2029 (e)
4.32 USD
-0.34 USD
-1.18 USD

Lifecore Biomedical business model & stock analysis

Landec Corp is a US-American company specialized in the development, manufacturing, and marketing of innovative products in the Agribusiness and Biotechnology sectors. It was founded in 1986 as a spin-off from the engineering faculty of Stanford University. The company follows a unique business model based on the integration of advanced technologies and biological processes. This aims to achieve sustainable agriculture that is both mindful of natural resources and achieves high yields. One of Landec's main divisions is the Fresh-Cut Products segment, where the company produces a variety of high-quality salads, vegetable, and fruit snacks that are distributed under the brand Eat Smart®. These products are known for their freshness, taste, and healthy nutritional values, and have gained high recognition in the USA. Another important business division of Landec is the Apio Packaging segment, specialized in the manufacturing and marketing of innovative packaging solutions for fresh fruits and vegetables. The packaging, distributed under the brand BreatheWay®, is equipped with a unique technology that regulates gas exchange within the package and extends the shelf life of the contents. In addition to these core segments, Landec is also active in the field of Biotechnology. Here, the company develops innovative products and technologies for use in human healthcare as well as the agricultural industry. An example of this is Apio's recently introduced whole plant juice called GreenWise™. Landec Corp is known for its innovation capabilities and its ability to develop new products and technologies. Throughout its history, the company has acquired a number of patents and awards and constantly strives to improve and advance its products. Overall, Landec Corp is a company that focuses on sustainability, innovation, and quality. With its unique business model and wide range of products and services, the company is well-positioned to continue growing and expanding its leadership position in the agriculture and biotechnology industry.

Lifecore Biomedical SWOT Analysis

Strengths

1. Strong market presence and well-established brand reputation.

2. Diversified product portfolio across different industries.

3. Robust research and development capabilities, leading to innovative and high-quality products.

Weaknesses

1. Reliance on a few major customers, making the company vulnerable to their changing demands or loss of contracts.

2. Limited geographic presence, mainly operating within specific regions.

3. Higher production costs compared to some competitors.

Opportunities

1. Growing demand for environmentally friendly products, providing an opportunity for the company's sustainable packaging solutions.

2. Expansion into new markets and industries, leveraging existing expertise and capabilities.

3. Acquisition or partnership opportunities to enhance product offerings or access new distribution channels.

Threats

1. Intense competition from both established players and new entrants in the industry.

2. Economic downturns or fluctuations in the market affecting consumer spending patterns.

3. Increasing regulations and compliance requirements impacting product development and manufacturing processes.

Lifecore Biomedical Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Lifecore Biomedical Employees
Details
Date
Lifecore Biomedical Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Lifecore Biomedical Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Lifecore Biomedical historical P/E ratio, EBIT multiple, and P/S ratio

Lifecore Biomedical annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Lifecore Biomedical shares outstanding

The number of shares of Lifecore Biomedical was 37.4 M in 2025. This indicates how many shares Lifecore Biomedical is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2022
30.30 M Stocks
Jan 1, 2023
30.46 M Stocks
Jan 1, 2024
34.36 M Stocks
Jan 1, 2025
37.40 M Stocks
Jan 1, 2026
37.48 M Stocks
Jan 1, 2027 (e)
37.48 M Stocks
Jan 1, 2028 (e)
37.48 M Stocks
Jan 1, 2029 (e)
37.48 M Stocks

Current Lifecore Biomedical forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
63.64 % (7)
Hold
36.36 % (4)
Sell
0.00 % (0)
12M Price Target
8.93
Last Price
4.84
Currency
USD
12M Return Potential
84.40 %
LTM Return
0 %

Lifecore Biomedical Analyst Rating Actions

DateFirmActionRating
6/16/2026
Barrington Research
Barrington Research
MaintainedOutperform
4/29/2026
Barrington Research
Barrington Research
MaintainedOutperform
3/27/2026
Barrington Research
Barrington Research
MaintainedOutperform
3/24/2026
Barrington Research
Barrington Research
MaintainedOutperform
3/17/2026
Barrington Research
Barrington Research
UpgradeMarket PerformOutperform
1/3/2025
Stephens & Co.
Stephens & Co.
MaintainedEqual Weight
11/22/2024
Craig-Hallum
Craig-Hallum
MaintainedBuy
8/28/2024
Barrington Research
Barrington Research
DowngradeOutperformMarket Perform
9/1/2023
Stephens & Co.
Stephens & Co.
MaintainedEqual Weight
9/1/2023
Barrington Research
Barrington Research
MaintainedOutperform

Lifecore Biomedical Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
4/8/2026-0.22USD-31.96 MUSD-2026 Q3
12/31/2025-0.19USD-32.99 MUSD-2026 Q2
5/30/20240.06USD-34.80 MUSD-2024 Q3
10/4/2023-0.23USD-25.04 MUSD-2024 Q1

EESG©

Eulerpool ESG Scorecard© for the Lifecore Biomedical stock

27/100
9
Environment
51
Social
22
Governance
E

Environment

20
Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Lifecore Biomedical shareholder structure

% Name
13.50765%
Wynnefield Capital, Inc.
Wynnefield Capital, Inc.
12.72821%
Legion Partners Asset Management, LLC
Legion Partners Asset Management, LLC
10.61157%
Greenhaven Road Investment Management, L.P.
Greenhaven Road Investment Management, L.P.
6.21061%
325 Capital LLC
325 Capital LLC
5.45678%
Laughing Water Capital, LP
Laughing Water Capital, LP
4.94608%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
...

Lifecore Biomedical Beneficial Ownership Filings (SEC 13D/G)

Free Float
90.3%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
17.10%
White Raymond T.
White Raymond T.
SEC ↗
17.10%
Kiper Christopher S
Kiper Christopher S
SEC ↗
16.90%
Legion Partners, LLC
Legion Partners, LLC
SEC ↗
16.60%
Raymond T. White
Raymond T. White
SEC ↗
16.60%
Christopher S. Kiper
Christopher S. Kiper
SEC ↗
15.60%
Legion Partners, L.P. I
Legion Partners, L.P. I
SEC ↗
9.80%
Greenhaven Road Investment Management, L.P.
Greenhaven Road Investment Management, L.P.
SEC ↗
7.89%
Jeffrey Bronchick
Jeffrey Bronchick
SEC ↗
7.89%
Cove Street Capital, LLC 27-5376591
Cove Street Capital, LLC 27-5376591
SEC ↗
6.74%
Aron R. English
Aron R. English
SEC ↗

Lifecore Biomedical Executives and Management Board

12 members · avg. age 59 · 17 % women

RL

Mr. Ryan Lake (47)

Chief Financial Officer

4.16 M USD

Management

TS

Mr. Thomas Salus (56)

Chief Legal and Administrative Officer , Secretary

4.10 M USD
PJ

Mr. Paul Josephs (60)

President, Chief Executive Officer, Director · since 2024

1.12 M USD
SD

Ms. Stephanie Diaz

Investor Relations · since 2024

Board of Directors

KH

Ms. Katrina Houde (67)

Independent Chairman of the Board

305,111.00 USD
JS

Mr. Joshua Schechter (52)

Independent Director

243,369.00 USD
NO

Mr. Nelson Obus (78)

Independent Director

215,003.00 USD
PJ

Mr. Paul Johnson (67)

Independent Director

206,117.00 USD
CK

Mr. Christopher Kiper (54)

Independent Director

205,578.00 USD
HA

Mr. Humberto Antunes (64)

Independent Director

203,910.00 USD

Frequently asked questions about Lifecore Biomedical

The business model of Landec Corp revolves around developing and commercializing innovative health and wellness solutions. Landec Corp primarily focuses on creating and selling differentiated products through two business segments: Curation Foods and Lifecore Biomedical. Curation Foods offers a wide range of plant-based foods, such as fresh packaged salads, vegetables, and fruit snacks, while Lifecore Biomedical specializes in developing and manufacturing various biomaterials and products for medical applications. With a commitment to sustainability and healthy living, Landec Corp aims to provide customers with high-quality, environmentally friendly products that enhance overall well-being.

Landec Corp is primarily active in the food packaging and biomaterial industries.

The main competitors of Landec Corp in the market include companies such as Archer-Daniels-Midland Company, Cargill Incorporated, and Ingredion Incorporated.

Landec Corp is a renowned company with a rich history and background. Founded in 1986, Landec Corp has grown to become a leading lifesciences company specializing in innovative health and wellness solutions. With headquarters in Menlo Park, California, Landec Corp focuses on the development and commercialization of differentiated products in various industries. The company is dedicated to solving challenges in agriculture, food, and biomedical materials through its proprietary technologies. Landec Corp has built a strong reputation for delivering high-quality, sustainable products, and its commitment to innovation has propelled its growth and success in the market.

Landec Corp has achieved several significant milestones throughout its history. One notable milestone was the acquisition of Lifecore Biomedical in 2013, which expanded their presence in the healthcare industry. Another important achievement was the introduction of the patented BreatheWay technology, which extended the shelf life of fresh produce. In addition, Landec Corp has successfully established strategic partnerships with major retailers, such as Walmart and Whole Foods, further enhancing their market reach. These accomplishments have solidified Landec Corp's position as a leading player in the technology-driven food and biomedical markets.

Landec Corp is primarily present in the United States.

Landec Corp represents a set of core values and a corporate philosophy focused on innovation, sustainability, and growth. The company prioritizes delivering innovative solutions and products that address the evolving needs of its customers. Landec Corp aims to contribute positively to the environment and society by employing sustainable practices across its operations. It actively invests in research and development to stay at the forefront of technology advancements, fostering growth opportunities. Through its commitment to operational excellence and customer satisfaction, Landec Corp strives to establish itself as a trusted leader in its industry.

Analysts currently set an average price target of 8.93 USD for the Lifecore Biomedical stock (median: 8.93 USD), implying +84.4 % versus the latest price. The consensus is based on 11 analyst ratings.

11 analysts currently rate the Lifecore Biomedical stock: 7 recommend buying, 4 holding and 0 selling.

Converted at the current exchange rate, the Lifecore Biomedical share trades at 4.19 EUR (4.84 USD).

The Lifecore Biomedical share (LFCR) is listed on 2 stock exchanges, including: NASDAQ (LNDC), Frankfurt (LDE.F).

Landec Corporation is a company specialized in the development and marketing of innovative and sustainable products in various areas. Its main divisions are Lifecore Biomedical and Curation Foods. Lifecore Biomedical produces medical devices and technologies for the field of regenerative medicine, such as implants, artificial joints, and other medical instruments. These products are developed and manufactured in collaboration with medical professionals, using advanced materials and technologies. On the other hand, Curation Foods operates in the food industry, offering different types of fruits and vegetables produced in a healthy and sustainable way. Some of Landec Corp's products include "Eat Smart" products from Curation Foods, which offer various vegetable and fruit salads as well as ready-to-eat meals. The company combines sustainable agriculture, modern processing methods, and innovative packaging design. Another product is IntelliBond, a special micronutrient additive for animal feed. Through patented technology, IntelliBond is designed to be better absorbed by animals, effectively preventing nutrient deficiencies. Landec Corp's business model aims to develop and market sustainable products that improve the health of people and animals while preserving the environment. The company emphasizes close collaboration between scientists, technology experts, and other professionals to develop innovative solutions tailored to the needs of customers and consumers. In addition, the company strives to integrate sustainability principles into its production and supply chains to reduce environmental impacts and conserve resources. This includes the use of recyclable materials and the promotion of projects to improve agriculture and environmental protection. Overall, Landec Corp offers a wide range of innovative and sustainable products in various sectors, focusing on the needs of customers and consumers. The company values sustainability, quality, and innovation, and relies on close collaboration among professionals from different fields to develop sustainable solutions.

The revenue of Lifecore Biomedical is 129.46 M USD. This figure is based on current financial data and reflects the company's business performance.

The profit of Lifecore Biomedical is -30.79 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Lifecore Biomedical is currently -5.89. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lifecore Biomedical stock.

The price-to-sales ratio (P/S) of Lifecore Biomedical is currently 1.40. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lifecore Biomedical stock.

The Eulerpool Quality Score for Lifecore Biomedical is 2/10.

The ISIN of Lifecore Biomedical is US5147661046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Lifecore Biomedical is 899376. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Lifecore Biomedical is LFCR. The ticker symbol is used to trade Lifecore Biomedical shares on the stock exchange.

Lifecore Biomedical paid dividends every year for the past 0 years.

Lifecore Biomedical is assigned to the 'Non-cyclical consumption' sector.

The dividends of Lifecore Biomedical are distributed in USD.